Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05510063 |
|
Recruitment Status :
Completed
First Posted : August 22, 2022
Last Update Posted : May 25, 2023
|
Sponsor:
Samsung Bioepis Co., Ltd.
Collaborator:
Organon and Co
Information provided by (Responsible Party):
Samsung Bioepis Co., Ltd.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | April 4, 2023 |
| Actual Study Completion Date : | May 4, 2023 |